CureVac Raises a Total of USD 640 Million in Private Financing Round
- Financing Round includes previously announced investments from German Federal Government and GSK for an amount of USD 514 million
- Additional USD 126 million raised, including participation of Qatar Investment Authority (QIA)
CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced the closing of its latest private financing round, raising a total of USD 640 million (560 million Euros). The financing round included previously announced equity investments by the German government via the Kreditanstalt für Wiederaufbau (KfW) with USD 343 million and GSK with USD 171 million as well as additional new equity investments from Qatar Investment Authority (QIA) and a group of existing and new investors with approximately USD 126 million.